The Cytokine Release Syndrome (Cytokine Storm) drugs in development market research report provides comprehensive information on the therapeutics under development for Cytokine Release Syndrome (Cytokine Storm), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cytokine Release Syndrome (Cytokine Storm). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cytokine Release Syndrome (Cytokine Storm) and features dormant and discontinued products.
GlobalData tracks 22 drugs in development for Cytokine Release Syndrome (Cytokine Storm) by 21 companies/universities/institutes. The top development phase for Cytokine Release Syndrome (Cytokine Storm) is preclinical with 11 drugs in that stage. The Cytokine Release Syndrome (Cytokine Storm) pipeline has 22 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cytokine Release Syndrome (Cytokine Storm) pipeline products market are: SFA Therapeutics, TheraBioPharma and HighTide Therapeutics.
The key targets in the Cytokine Release Syndrome (Cytokine Storm) pipeline products market include Interleukin 6 Receptor Subunit Alpha, Interleukin 6, and Interleukin 1 Receptor Type 1.
The key mechanisms of action in the Cytokine Release Syndrome (Cytokine Storm) pipeline product include Interleukin 6 Receptor Subunit Alpha Antagonist with two drugs in Pre-Registration. The Cytokine Release Syndrome (Cytokine Storm) pipeline products include 11 routes of administration with the top ROA being Intravenous and six key molecule types in the Cytokine Release Syndrome (Cytokine Storm) pipeline products market including Small Molecule, and Monoclonal Antibody.
Cytokine Release Syndrome (Cytokine Storm) overview
Cytokine release syndrome (CRS) is a systemic inflammatory response, potentially life-threatening and triggered by various factors like infections and specific drugs. It can occur following the administration of natural and bispecific antibodies, as well as adoptive T-cell therapies for cancer. CRS is characterized by elevated levels of cytokines, including interleukin (IL)-6 and interferon γ. Tocilizumab, an anti-IL-6 receptor antibody, coupled with corticosteroids, has shown promise in reversing CRS, but its early and aggressive use may compromise the efficacy of immunotherapy. Therefore, current strategies aim to judiciously administer immunosuppressive therapy, focusing on patients facing severe consequences of the syndrome.
For a complete picture of Cytokine Release Syndrome (Cytokine Storm)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
